Monoclonal antibodies lock down SARS-CoV-2 spike

descriptionPublicationkeyboard_double_arrow_right Article 01 Nov 2023 English Publisher:Elsevier BVJournal:Trends in Immunology, volume 44, pages 874-876 (issn: 1471-4906,

Copyright policy )Funded by:EC | B-DOMINANCE, VR | unidentified, kawforskning | unidentified

Authors: Huang, Hsiang-Chi; Angeletti, Davide;

doi: 10.1016/j.it.2023.09.006

pmid: 37805348

Monoclonal antibodies lock down SARS-CoV-2 spike

- Summary
- Subjects
- Metrics

Abstract

SARS-CoV-2 rapidly accumulated mutations in its immunodominant receptor-binding domain (RBD), rendering all clinically authorized monoclonal antibodies (mAbs) ineffective. Liu et al. unveil potent human mAbs that neutralize all tested SARS-CoV-2 variants by locking the Spike protein RBD in a downward conformation, thus inhibiting receptor engagement.

Related Organizations

University of Gothenburg
Sweden

Keywords

SARS-CoV-2, Immunodominant Epitopes, Communicable Disease Control, Humans, COVID-19, Antibodies, Monoclonal, Antibodies, Viral, Antibodies, Neutralizing

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	0
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average